The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

USC study finds exposure to “forever chemical” PFAS linked to liver cancer in humans

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Keck School of Medicine of USC researchers find that a common man-made polyfluoroalkyl substance (PFAS) may elevate risk of liver cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Liver cancer growth tied to tryptophan intake in mice

Researchers at UT Southwestern Medical Center have discovered that a diet free of the amino acid tryptophan can effectively halt the growth of liver cancer in mice. Their findings, published in Nature Communications, offer new insights for dietary-based cancer treatments and highlight the critical role of the tryptophan metabolite indole 3-pyruvate (I3P) in liver tumor development.
Clinical Roundup

Imfinzi regimen reduces the risk of disease progression or death in liver cancer eligible for embolization

Positive results from the EMERALD-1 phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with transarterial chemoembolization, or TACE, and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival compared to TACE alone in patients with hepatocellular carcinoma eligible for embolization.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account